+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bloodstream Infection Testing Market by Product, Technology, End User, Application - Global Forecast to 2030- Product Image
Bloodstream Infection Testing Market by Product, Technology, End User, Application - Global Forecast to 2030- Product Image
Sale

Bloodstream Infection Testing Market by Product, Technology, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977727
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bloodstream Infection Testing Market grew from USD 1.20 billion in 2024 to USD 1.30 billion in 2025. It is expected to continue growing at a CAGR of 7.73%, reaching USD 1.88 billion by 2030.

Setting the Stage for Bloodstream Infection Testing

Bloodstream infections pose a relentless challenge to patient safety and healthcare systems worldwide. As pathogens evolve and antimicrobial resistance surges, the demand for rapid, reliable diagnostic testing has never been more urgent. Modern diagnostic laboratories and point-of-care settings alike require solutions that balance speed, accuracy, and cost-effectiveness. The convergence of technological advancements, regulatory scrutiny, and shifting reimbursement frameworks has elevated bloodstream infection testing from a routine clinical practice to a dynamic arena of innovation. This executive summary offers a concise yet insightful overview of the market forces driving this evolution, underscoring the critical role of early detection in improving patient outcomes and reducing overall healthcare expenditures.

In the chapters that follow, we explore how emerging technologies are redefining diagnostic workflows, how economic policies such as the new United States tariffs are reshaping supply chains, and how nuanced segmentation across products, technologies, end users, and applications can inform strategic decision-making. Grounded in rigorous research and expert validation, this analysis aims to equip industry leaders with the clarity and foresight needed to navigate an increasingly complex landscape.

Paradigm Shifts Reshaping the Testing Landscape

The bloodstream infection testing arena is undergoing a profound transformation as diagnostic paradigms shift from conventional culture methods toward integrated, high-throughput platforms. Automation and digital connectivity now play pivotal roles in enabling near real-time surveillance and rapid pathogen identification. Molecular techniques such as PCR and next-generation sequencing have transitioned from specialized research settings into mainstream clinical laboratories, delivering unprecedented sensitivity and genomic insights that inform targeted antimicrobial therapy. Meanwhile, the maturation of biosensor platforms has ushered in portable electrochemical and optical devices capable of point-of-care deployment, bringing testing closer to the patient and reducing turnaround times.

Concurrently, mass spectrometry has evolved into a cornerstone of speciation workflows, with MALDI-ToF MS systems streamlining identification processes that once took days. These technologies are increasingly integrated within software ecosystems that leverage machine learning algorithms for predictive analytics and decision support. As regulatory bodies adapt to these innovations, interoperability standards and quality metrics are being refined to ensure consistent performance across diverse laboratory settings. Transitioning from manual to automated culture systems further accelerates pathogen detection, reducing labor burdens and human error. Collectively, these shifts are redefining operational models and setting new benchmarks for diagnostic excellence.

Unpacking the 2025 US Tariff Impacts on the Testing Ecosystem

The implementation of the United States’ 2025 tariff regime has introduced pronounced cost pressures across the bloodstream infection testing value chain. Instruments, reagents, kits, and consumables subject to additional duties have experienced upward pricing trends that reverberate through procurement and budgeting processes. These elevated costs have prompted many organizations to reassess supplier portfolios, pursue near-shoring strategies, and renegotiate contracts to mitigate margin erosion. Laboratory managers now face the dual challenge of preserving test affordability while maintaining the stringent quality standards mandated for clinical diagnostics.

Beyond procurement, the tariff impacts extend to research collaborations and cross-border shipment of biological samples. Bioinformatics software and integrated analytics tools, often licensed internationally, are encountering new licensing costs that affect the total cost of ownership. Regulatory agencies are monitoring these shifts closely, evaluating whether tariff-induced price fluctuations could impede access to critical diagnostics and compromise public health surveillance. In response, some diagnostic providers are accelerating their investments in domestic manufacturing capabilities, while others are exploring modular platform designs that localize critical components and minimize import dependencies. These adaptations underscore the strategic imperative of building resilience into the diagnostic supply chain.

Delving into Product, Technology, End User, and Application Segmentation

A granular understanding of the bloodstream infection testing market emerges through its distinct segmentation across products, technologies, end users, and applications. In terms of product, the market encompasses sophisticated instruments that form the backbone of diagnostic workflows, a diverse range of reagents and kits designed for pathogen detection and antimicrobial susceptibility testing, and advanced software solutions that integrate data management and decision support. Examining technology reveals a landscape that spans biosensor platforms-comprising electrochemical and optical biosensors-culture based systems that include both automated culture systems and manual culture methods, mass spectrometry anchored by MALDI-ToF MS, and molecular diagnostics leveraging next-generation sequencing and polymerase chain reaction.

End-user segmentation highlights the distinct needs of academic and research institutes pursuing fundamental microbial studies, hospital laboratories tasked with urgent clinical diagnostics, point of care testing environments requiring rapid, user-friendly assays, and reference laboratories offering specialized confirmatory services. Application-based categorization captures the spectrum from clinical diagnosis, where diagnostic accuracy can be a matter of life and death, to research settings exploring pathogen biology and resistance mechanisms, and surveillance and monitoring programs that track infection trends across populations. Integrating these segmentation lenses allows stakeholders to tailor product development, market entry, and resource allocation strategies that align with specific operational requirements and growth opportunities.

Regional Dynamics Shaping Market Trajectories

Regional market dynamics are shaped by distinct regulatory frameworks, healthcare infrastructure maturity, and investment priorities. In the Americas, robust reimbursement policies, expansive healthcare networks, and a high prevalence of healthcare-associated infections drive demand for rapid, high-throughput diagnostic solutions. Latin American markets are demonstrating growing interest in cost-effective point-of-care technologies that bridge resource gaps.

Meanwhile, Europe, the Middle East & Africa exhibit fragmentation in regulatory approvals and healthcare delivery models. Western European nations emphasize stringent performance validation and interoperability standards, while emerging markets in the Middle East and Africa prioritize affordable, portable platforms that can address infectious disease challenges in diverse environments. Cross-regional collaborations and public-private partnerships are expanding to enhance diagnostic capacity and surveillance.

Asia-Pacific stands out for its aggressive adoption of cutting-edge molecular diagnostics and mass spectrometry platforms, fueled by substantial public health investments and an expanding network of research hospitals. Countries like China, Japan, and India are not only consumers but also increasingly significant innovators in assay development and instrumentation. Together, these regional nuances inform market entry strategies and partnership models, enabling tailored solutions that resonate with local stakeholders and address unique epidemiological profiles.

Competitive Landscape and Leading Innovators

The competitive landscape in bloodstream infection testing is defined by strategic investments, product innovation, and mergers and acquisitions aimed at consolidating capabilities across platforms. Key industry leaders have pursued portfolio expansions that span rapid molecular assays, automated culture systems, and integrated data analytics solutions. Collaborations with academic institutions and contract research organizations have accelerated the translation of novel biomarkers into market-ready assays. Companies are investing heavily in R&D to drive miniaturization of biosensor technologies and to refine machine learning algorithms that enhance diagnostic accuracy and predictive performance.

To maintain a competitive edge, leading organizations are adopting agile development methodologies, enabling faster iteration of new assays and instrument upgrades. Geographic expansion strategies are targeting underserved markets through local manufacturing partnerships and tailored pricing models that account for regional economic conditions. Intellectual property portfolios around proprietary reagents, multiplexed panels, and software algorithms are being fortified through strategic patent filings. These concerted efforts underscore the high stakes of differentiation in a market where time-to-result, cost per test, and ease of use can determine adoption across diverse clinical and research environments.

Strategic Actions to Thrive in a Complex Environment

To thrive in this complex ecosystem, industry leaders should prioritize diversification of manufacturing and sourcing to buffer against tariff-related disruptions. Investing in modular platform architectures can localize production of critical components, reducing reliance on imports while maintaining global standardization. A strategic focus on next-generation molecular assays and miniaturized biosensors will meet the growing demand for rapid, decentralized testing. Collaborations with academic and reference laboratories can accelerate validation studies and broaden clinical utility across indications.

Furthermore, integrating advanced analytics and digital connectivity into diagnostic workflows will enhance operational efficiency and support real-time surveillance initiatives. Tailoring pricing and service models to regional economic realities can unlock adoption in emerging markets, while advocacy for harmonized regulatory pathways will mitigate approval delays. Finally, building strategic alliances with healthcare providers, public health agencies, and patient advocacy groups will reinforce market positioning and amplify the impact of innovative testing solutions.

Methodical Approach Underpinning the Analysis

This analysis builds upon a rigorous, multi-phased research methodology designed to ensure comprehensive coverage and actionable insights. The process began with an extensive review of peer-reviewed literature, regulatory filings, and technical white papers to map the landscape of diagnostic technologies and emerging trends. Primary research included in-depth interviews with industry executives, laboratory directors, and clinical microbiologists to validate market drivers, segmentation criteria, and competitive strategies.

Quantitative data was triangulated from proprietary databases, supplier price bulletins, and trade association reports to identify cost structures and supply chain dynamics. Regional market intelligence was enriched through local stakeholder consultations and field surveys to capture nuances in regulatory environments and end-user preferences. A final validation round involved cross-functional workshops with subject-matter experts to refine the segmentation framework and ensure alignment with real-world diagnostic workflows. Quality assurance measures, including editorial peer review and data accuracy checks, underpin the credibility of the findings presented herein.

Synthesizing Insights for Decision-Makers

The bloodstream infection testing market stands at a pivotal juncture, driven by technological breakthroughs, evolving regulatory landscapes, and macroeconomic forces such as the new tariff structure. Rapid molecular diagnostics, biosensor miniaturization, and mass spectrometry innovations are redefining the standards for speed, sensitivity, and operational efficiency. Nuanced segmentation across products, technologies, end users, and applications reveals targeted opportunities for strategic growth and partnership.

Region-specific dynamics underscore the importance of adaptable business models that reflect local healthcare priorities and economic conditions. The competitive arena is marked by vigorous R&D investment, sophisticated M&A activity, and a relentless focus on differentiation through integrated software and data analytics. By embracing the actionable recommendations outlined here-ranging from supply chain resilience to digital integration-industry stakeholders can navigate uncertainty and capitalize on emerging trends. This synthesis equips decision-makers with the informed perspective necessary to chart a clear path toward sustainable growth and clinical impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Instruments
    • Reagents & Kits
    • Software
  • Technology
    • Biosensor Platforms
      • Electrochemical Biosensors
      • Optical Biosensors
    • Culture Based Systems
      • Automated Culture Systems
      • Manual Culture Methods
    • Mass Spectrometry
      • MALDI ToF Ms
    • Molecular Diagnostics
      • Next Generation Sequencing
      • PCR
  • End User
    • Academic & Research Institutes
    • Hospital Laboratories
    • Point Of Care Testing
    • Reference Laboratories
  • Application
    • Clinical Diagnosis
    • Research
    • Surveillance & Monitoring
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Becton Dickinson and Company
  • bioMérieux SA
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Luminex Corporation
  • QIAGEN N.V.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bloodstream Infection Testing Market, by Product
8.1. Introduction
8.2. Instruments
8.3. Reagents & Kits
8.4. Software
9. Bloodstream Infection Testing Market, by Technology
9.1. Introduction
9.2. Biosensor Platforms
9.2.1. Electrochemical Biosensors
9.2.2. Optical Biosensors
9.3. Culture Based Systems
9.3.1. Automated Culture Systems
9.3.2. Manual Culture Methods
9.4. Mass Spectrometry
9.4.1. MALDI ToF Ms
9.5. Molecular Diagnostics
9.5.1. Next Generation Sequencing
9.5.2. PCR
10. Bloodstream Infection Testing Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Hospital Laboratories
10.4. Point Of Care Testing
10.5. Reference Laboratories
11. Bloodstream Infection Testing Market, by Application
11.1. Introduction
11.2. Clinical Diagnosis
11.3. Research
11.4. Surveillance & Monitoring
12. Americas Bloodstream Infection Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Bloodstream Infection Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Bloodstream Infection Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Becton Dickinson and Company
15.3.2. bioMérieux SA
15.3.3. F. Hoffmann-La Roche AG
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. Siemens Healthineers AG
15.3.6. Abbott Laboratories
15.3.7. Danaher Corporation
15.3.8. Bio-Rad Laboratories, Inc.
15.3.9. Luminex Corporation
15.3.10. QIAGEN N.V.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BLOODSTREAM INFECTION TESTING MARKET MULTI-CURRENCY
FIGURE 2. BLOODSTREAM INFECTION TESTING MARKET MULTI-LANGUAGE
FIGURE 3. BLOODSTREAM INFECTION TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOODSTREAM INFECTION TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 55. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 56. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 57. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 58. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 59. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 129. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 130. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 131. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 132. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 184. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 185. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 186. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 187. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 188. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 191. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 247. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 249. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 250. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 251. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 252. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 272. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 274. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 275. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 277. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 280. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 282. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 284. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 285. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. INDIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY

Companies Mentioned

The companies profiled in this Bloodstream Infection Testing market report include:
  • Becton Dickinson and Company
  • bioMérieux SA
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Luminex Corporation
  • QIAGEN N.V.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.88 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bloodstream Infection Testing - Global Strategic Business Report - Product Image

Bloodstream Infection Testing - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Bloodstream Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Bloodstream Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
North America Bloodstream Infection Testing Market, By Country, Competition, Forecast & Opportunities, 2019-2029F - Product Image

North America Bloodstream Infection Testing Market, By Country, Competition, Forecast & Opportunities, 2019-2029F

  • Report
  • 132 Pages
  • North America
From
Blood Culture Test Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User - Product Image

Blood Culture Test Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User

  • Report
  • 142 Pages
  • Global
From
Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033 - Product Image

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From

About the Bloodstream Infection Test Market

The Bloodstream Infection Test market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of bacteria, fungi, and viruses in the bloodstream. The test is typically performed on a sample of blood taken from a patient, and the results are used to diagnose and treat infections. The test can also be used to monitor the effectiveness of treatments. The Bloodstream Infection Test market is highly competitive, with a range of products available from different manufacturers. These products vary in terms of accuracy, cost, and turnaround time. The market is also subject to regulatory requirements, which can affect the availability of certain products. Some companies in the Bloodstream Infection Test market include Abbott, Becton Dickinson, Cepheid, DiaSorin, Hologic, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.